ClinicalTrials.gg
Not yet recruitingNCT06525272Updated Jul 29, 2024

A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of OsrhCT in Patients With Pleurisy

A Phase 1 interventional study of Recombinant Human Chymotrypsin(OsrhCT) and Placebo for Recombinant Human Chymotrypsin(OsrhCT) in Pleurisy, sponsored by Healthgen Biotechnology Corp.. Not yet recruiting at 4 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-07-29.

Sponsored by Healthgen Biotechnology Corp. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Primary Objectives:

To evaluate the safety and tolerability of single and multiple ascending doses of OsrhCT administered intrathoracically in patients with pleurisy, and to explore the DLT, MTD, and recommended effective dose of OsrhCT.

Secondary Objectives:

To evaluate the preliminary efficacy of single and multiple intrathoracic doses of OsrhCT.

Population:

Patients diagnosed with pleurisy requiring chest tube drainage.

Investigational Products:

Investigational Drug: Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, 4,000U/vial, freeze-dried powder, stored at 2-8°C.

Placebo:

Placebo for Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, freeze-dried powder, stored at 2-8°C.

Study Design:

The study comprises two parts: Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD), both employing a multicenter, randomized, double-blind, and placebo-controlled design.

Sample Size:

A total of 72 subjects (both male and female) are expected to be enrolled in this trial, including 48 subjects for single-dose administration and 24 subjects for multiple-dose administration.

Read the detailed description

Primary Objectives:

To evaluate the safety and tolerability of single and multiple ascending doses of OsrhCT administered intrathoracically in patients with pleurisy, and to explore the DLT, MTD, and recommended effective dose of OsrhCT.

Secondary Objectives:

To evaluate the preliminary efficacy of single and multiple intrathoracic doses of OsrhCT.

Population:

Patients diagnosed with pleurisy requiring chest tube drainage.

Investigational Products:

Investigational Drug: Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, 4,000U/vial, freeze-dried powder, stored at 2-8°C.

Placebo:

Placebo for Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, freeze-dried powder, stored at 2-8°C.

Indication:

Pleurisy

Sample Size:

A total of 72 subjects (both male and female) are expected to be enrolled in this trial, including 48 subjects for single-dose administration and 24 subjects for multiple-dose administration.

Study Design:

The study comprises two parts: Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD), both employing a multicenter, randomized, double-blind, and placebo-controlled design.

Single Ascending Dose (SAD) Study:

Eligible pleurisy patients will receive a single intrathoracic injection of different doses of OsrhCT to evaluate safety and tolerability. There are six dose groups (2000U, 4000U, 8000U, 12000U, 16000U, 20000U). If the previous dose group shows good tolerance and safety, the next dose group will be enrolled.

The plan is to enroll 48 subjects in this phase, with 8 subjects per dose group (6 receiving intrathoracic injection of OsrhCT and 2 receiving intrathoracic injection of placebo). Each subject can only receive administration in one dose group, and repeated administration is not allowed.

Each subject will be evaluated by the investigator based on their condition during the screening process to determine the necessity of chest tube drainage or confirm their current use of a chest tube drainage. Subsequently, the investigational drug will be administered into the pleural cavity following a baseline chest X-ray. After administration, the chest tube will be clamped for 6 hours. After 6 hours, the chest tube will be opened for drainage. Subjects are allowed to clamp the drainage tube for sleeping or going out for examination. The drainage of pleural effusion will be recorded in detail. Safety checks will be performed on Day 2, and a comprehensive safety check will be performed on Day 7. Subjects will be discharged from the study if the investigator evaluates that there are no drug-related safety issues. The administration of fibrinolytic agents into the pleural cavity is prohibited before Day 7.

Multiple Ascending Dose (MAD) Study:

Eligible pleurisy patients will receive multiple intrathoracic injections of different doses of OsrhCT to evaluate safety, tolerability, and preliminary efficacy. Based on the tolerability results from the SAD study, three dose groups (low, medium, and high) will be selected for multiple dosing. Each subject will receive only one dose group and no repeat dosing. If the previous dose group shows good tolerance and safety, the next dose group will be enrolled.

The plan is to enroll 24 subjects in this phase, with 6 subjects per dose group receiving OsrhCT and 2 subjects receiving placebo. Each subject will receive the drug once daily for three consecutive days.

Each subject will be evaluated by the investigator based on their condition during the screening process to determine the necessity of chest tube drainage or confirm their current use of a chest tube drainage. Subsequently, the investigational drug will be administered into the pleural cavity following a baseline chest X-ray. The drug is administered once a day for up to 3 days, and the interval between the two administrations is 24h±1h. If pleural effusion is completely resolved before the third dose, early termination of drug administration is allowed, and the subject can enter the follow-up period. After each administration, the chest tube will be clamped for 6 hours. After 6 hours, the chest tube will be opened for drainage. Subjects are allowed to clamp the drainage tube for sleeping or going out for examination. The drainage of pleural effusion will be recorded in detail. After the last dose, subjects will be observed in the hospital for at least 4 days. Comprehensive safety checks will be performed on Day 7 and Day 30. Subjects will be discharged from the study at Day 30 if there is no safety problem as evaluated by the investigator. The administration of fibrinolytic agents into the pleural cavity is prohibited before Day 7.

Dosing Plan:

Investigational drug preparation: Dissolve the corresponding dose of the investigational drug in 20ml of normal saline for later use.All subjects will undergo chest tube drainage before the investigational drug administration. For subjects who meet the enrollment conditions, 20ml of the prepared drug will be injected into the thoracic cavity through a chest tube. After the injection is completed, the tube will be flushed with 5ml of normal saline, and then the chest tube will be clamped. Subjects will be advised to change positions to ensure adequate drug contact with the pleura (position changes are not mandatory).

Outcome Measures:

Safety Outcome Measures:

AE and SAE; Physical examination; Vital signs; Laboratory tests (complete blood count, blood biochemistry, coagulation function, and urinalysis); 12-lead ECG.

Efficacy Outcome Measures:

Changes in pleural opacity area on chest X-ray (measured as the absolute change from baseline in the percentage of pleural opacity area in the ipsilateral half of the chest on chest X-ray from pre-administration to Day 7); Relative change in pleural opacity area on chest X-ray (measured as the percentage reduction of the baseline area from pre-administration to Day 7); Drainage of pleural effusion from the first administration to Day 7; Changes in inflammatory markers (white blood cell count and C-reactive protein) before and after treatment.

02

Conditions studied

  • Pleurisy

Keywords

  • OsrhCT
  • Recombinant Human Chymotrypsin
03

In context

Lead sponsor

Healthgen Biotechnology Corp. is the lead sponsor of 8 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary participation with signed ;
  2. Aged 18-65 years (inclusive), male or female;
  3. Clinical diagnosis of pleurisy (parapneumonic pleural effusion, empyema, tuberculous pleurisy, etc.);
  4. Patients with pleural effusion confirmed by chest ultrasound or CT examination and requiring chest tube drainage as assessed by the study physician, and the ultrasound report or CT image within one month shows that there are fibrous bands or encapsulated or septated effusions in the thoracic cavity;
  5. Patients who cannot be fully drained after open drainage for ≥ 3 hours after chest tube drainage and meet the following conditions: The maximum depth of pleural effusion detected by ultrasound is ≥ 2 cm;
  6. Women of must agree to use (such as intrauterine device, contraceptive pills or condoms) during the study and within 3 months after the end of the study; men must agree to use effective contraception during the study and within 3 months after the end of study period.

Exclusion criteria

Exclusion Criteria:

  1. Known allergy to the drug or its ;
  2. Known or clinically highly suspected malignant pleural effusion;
  3. Received intrathoracic injection of fibrinolytic drugs (such as urokinase, streptokinase, and alteplase) within 1 month prior to enrollment;
  4. History of lung resection surgery on the same side as the chest tube drainage;
  5. Evidence of abdominal lesions (e.g., pancreatic cyst or renal cyst) communicating with the pleura;
  6. Currently using systemic and unable to discontinue;
  7. antibody positive;
  8. History of organ transplantation;
  9. Severe cardiovascular, cerebrovascular, hematologic diseases, or ;
  10. Abnormal laboratory values: \<80g/L, total >2× (upper limit of normal), >2.5×ULN, AST >2.5×ULN, creatinine >2×ULN; coagulation function >1.5×ULN, or INR >1.5;
  11. Pregnant or breastfeeding women;
  12. Subjects who have participated in any drug clinical trial and received treatment within the last 3 months (excluding diagnostic skin test);
  13. Any other conditions deemed unsuitable for the study by the investigator.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Recombinant Human Chymotrypsin(OsrhCT)

    Recombinant Human Chymotrypsin (OsrhCT), freeze-dried powder, 4,000U/vial Single Ascending Dose (SAD) Study: 20ml of the prepared drug will be injected into the thoracic cavity through a chest tube.There are six dose groups (2000U, 4000U, 8000U, 12000U, 16000U, 20000U),each subject can only receive administration in one dose group, and repeated administration is not allowed. Multiple Ascending Dose (MAD) Study: 20ml of the prepared drug will be injected into the thoracic cavity through a chest tube.three dose groups (low, medium, and high) will be selected for multiple dosing. Each subject will receive only one dose group and no repeat dosing.

    Drug: Recombinant Human Chymotrypsin(OsrhCT)

  • Placebo comparator
    Placebo for Recombinant Human Chymotrypsin

    Placebo for Recombinant Human Chymotrypsin (OsrhCT), freeze-dried powder Single Ascending Dose (SAD) Study: 20ml of the prepared drug will be injected into the thoracic cavity through a chest tube.There are six dose groups ,each subject can only receive administration in one dose group, and repeated administration is not allowed. Multiple Ascending Dose (MAD) Study: 20ml of the prepared drug will be injected into the thoracic cavity through a chest tube.three dose groups (low, medium, and high) will be selected for multiple dosing. Each subject will receive only one dose group and no repeat dosing.

    Drug: Placebo for Recombinant Human Chymotrypsin(OsrhCT)

Interventions

  • DrugRecombinant Human Chymotrypsin(OsrhCT)

    Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, 4,000U/vial, freeze-dried powder, 20ml of the prepared drug will be injected into the thoracic cavity through a chest tube.

    Also known as: Freeze-dried Powder of Recombinant Human Chymotrypsin(OsrhCT)

  • DrugPlacebo for Recombinant Human Chymotrypsin(OsrhCT)

    Placebo for Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, freeze-dried powder, stored at 2-8°C.

    Also known as: Freeze-dried Powder of Placebo for Recombinant Human Chymotrypsin(OsrhCT)

06

What researchers measure

Primary outcomes

  1. Safety Outcome Measures

    Incidence of AE

    Time frame: Single Ascending Dose (SAD) Study:7days;Multiple Ascending Dose (MAD) Study:30days

Secondary outcomes

  1. Efficacy Outcome Measures:Changes in pleural opacity area on chest X-ray

    Measured as the absolute change from baseline in the percentage of pleural opacity area in the ipsilateral half of the chest on chest X-ray from pre-administration to Day 7

    Time frame: 7 days

  2. Efficacy Outcome Measures:Relative change in pleural opacity area on chest X-ray

    Relative change in pleural opacity area on chest X-ray (measured as the percentage reduction of the baseline area from pre-administration to Day 7)

    Time frame: 7 days

  3. Efficacy Outcome Measures:Drainage of pleural effusion

    Drainage of pleural effusion from the first administration to Day 7

    Time frame: 7 days

  4. Efficacy Outcome Measures:Changes in inflammatory markers

    White blood cell count and C-reactive protein before and after treatment

    Time frame: 7 days

07

Study locations

4 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2024; primary completion for Jul 2025, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2024
First posted
Jul 29, 2024
StartEst.
Jul 2024
Primary completionEst.
Jul 2025
CompletionEst.
Dec 2025
Last update
Jul 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06525272
Lead sponsor
Healthgen Biotechnology Corp.
Responsible party
Sponsor
First posted
Jul 29, 2024
Start date
Jul 2024 (estimated)
Primary completion
Jul 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Jul 29, 2024

Study contacts

Shuihua Lu, MD
Contact
lushuihua66@126.com
+8613397122613
Xuerong Chen, MD
Contact
384481688@qq.com
+8613266782686
Shuihua Lu, MD
principal investigator · Shenzhen Third People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion